SP 5M 002
Alternative Names: SP-5M-002Latest Information Update: 12 Jul 2024
At a glance
- Originator Shin Poong Pharmaceutical
- Class Adjuvants; Antirheumatics
- Mechanism of Action Hyaluronic acid modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Osteoarthritis
Most Recent Events
- 03 May 2024 Phase-III clinical trials in Osteoarthritis in South Korea (Intra-articular) (NCT06399042)